ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

UroViu Receives FDA 510(k) Clearance for Its UV5000 Advanced Endoscope Platform

UroViu Corporation is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its UV5000 cordless, single-use endoscope platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250930782166/en/

The UV5000 replaces the current UV4500 on the market, offering a faster processor, longer battery life, and brighter HD visualization directly within the clinician's line of sight. It is compatible with all of UroViu's single-use endoscope cannulas, graspers, and biopsy forceps. As a companion to the UV5000, UroViu has submitted a 510(k) application for a model, the UV5000W, that has built-in Wi-Fi connectivity to external displays.

Bruce OuYang, Ph.D., CEO, commented, "UroViu strives to achieve a win-win situation for patients and care providers and has gained adoption across all segments of the market, including private practices, ASCs, academic institutions, VA, and DOD healthcare facilities, benefiting from the following unique features:

  • Cordless, untethered design: This minimizes the environmental impact and carbon footprint of disposable products by eliminating any cords. The profile and weight of all our disposables are half or a third compared to similar products on the market.
  • Portability and Simplicity: The UV5000 turns any room into a procedure room. This allows for schedule expansion, creating efficiency benefiting both the practice and patients.
  • Versatile platform: The UV5000 platform allows for fast additions of new single-use cannulas optimized for various indications, aiming to provide a complete set of tools for users without investing in additional reusable devices."

The UV5000 is now available in the U.S. market. For more information or to schedule a hands-on demonstration, please contact UroViu's sales representatives or customer service as listed on https://www.uroviu.com.

UroViu Corp., based in Los Altos, California, develops, manufactures, and commercializes advanced single-use endoscopic visualization solutions worldwide. The company pioneered the world's most portable cystoscopy platform that is always ready, eliminating the need for reprocessing, capital equipment, servicing, and advance scheduling. UroViu's mission is to simplify workflows and expand access to high-quality endoscopy by integrating cutting-edge technologies, including edge AI and robotics.

Contacts

Media contact:

Bruce OuYang, Ph.D.

Chairman and CEO

Email: bxo@uroviu.com

Mobile: 650-283-2778

Office: 650-878-6686

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.